At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 17 enrolled
Drug / intervention
PF-07321332 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-07321332 BOOSTED WITH RITONAVIR IN ADULT PARTICIPANTS WITH MODERATE HEPATIC IMPAIRMENT AND HEALTHY PARTICIPANTS WITH NORMAL HEPATIC FUNCTION
In Brief
A Phase 1 clinical trial evaluating PF-07321332 and Ritonavir for Hepatic Impairment. Completed, enrolled 17 participants across 2 sites.
Detailed Summary
The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of hepatic impairment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Impairment
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartAug 2021
Primary CompletionDec 2021
TodayJul 2026
First PostedAug 13, 2021
Enrollment StartAug 31, 2021
Primary CompletionDec 7, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.9 years ago
Interventions
PF-07321332drug
Tablet
Ritonavirdrug
PK Boosting agent